Latest News

Keep up to date with the latest news from Pilatus Biosciences.

News

March 12, 2026

Pilatus Biosciences Announces First Patient Dosed in Phase 1 Trial of First-in-Class Metabolic Checkpoint Antibody PLT012 in Solid Tumors

February 19, 2026

Pilatus Biosciences Receives FDA Fast Track Designation for Metabolic Checkpoint Inhibitor PLT012 in Hepatocellular Carcinoma

December 15, 2025

Pilatus Biosciences Announces FDA Clearance of IND Application for PLT012, a First-in-Class Anti-CD36 Metabolic Checkpoint Antibody in Solid Tumors

December 8, 2025

Pilatus Biosciences is Selected for LabCentral New Cambridge-Based Educational Program

Upcoming Events

March 24, 2026

-

March 25, 2026

QEII Centre, London, UK

NextGen Biomed 2026

More Info

April 17, 2026

-

April 22, 2026

San Diego

AACR Annual Meeting San Diego

More Info